Psychology class: Indivior aims to move primary listing from London to New York
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
This article picked by a teacher with suggested questions is part of the Financial Times free schools access programme. Details/registration here.
Read all our psychology class picks.
Specification:
Schizophrenia
Click the link below to read the and then answer the questions:
Indivior aims to move primary listing from London to New York
Indivior, the company discussed in the article, produces medication for schizophrenia. Explain how antipsychotics work. You may wish to draw a diagram
Distinguish between typical and atypical drugs as used in the treatment of schizophrenia
Explain two limitations of drug therapy for schizophrenia
The article gives Indivior’s adjusted net income of over $220mn for 2023. Some of this may be used to fund research into drug therapy. Explain what is meant by publication bias
In 2020, the company agreed to a large settlement based on false safety claims about one of their (anti-addiction) drugs. To what extent do side effects undermine the effectiveness and appropriateness of schizophrenia medication?
Danny Galbraith, St Bartholomew’s School
Comments